Patents Assigned to Cognetix, Inc.
-
Patent number: 6767895Abstract: The invention relates to relatively short peptides (termed I-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.Type: GrantFiled: June 29, 2001Date of Patent: July 27, 2004Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: Craig S. Walker, Reshma Shetty, Elsie C. Jimenez, J. Michael McIntosh, Baldomero M. Olivera, Maren Watkins, Robert M. Jones, Gregory S. Shen
-
Patent number: 6762165Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: December 28, 2000Date of Patent: July 13, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, G. Edward Cartier, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Richard T. Layer, Robert M. Jones
-
Publication number: 20040132663Abstract: The invention relates to &ohgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: January 29, 2004Publication date: July 8, 2004Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier
-
Publication number: 20040092447Abstract: The invention relates to uses of kappa-conotoxin PVIIA (&kgr;-PVIIA), analogs and derivatives for activating ATP-sensitive K+ channels. The activation of ATP-sensitive K+ channels is useful for opening KATP channels which can be used to treat a wide range of disease and injury states, including cerebral and cardiac ischemia and asthma.Type: ApplicationFiled: July 28, 2003Publication date: May 13, 2004Applicant: Cognetix, Inc.Inventors: Ann H. Cornell-Bell, Karen E. Pemberton, Davis L. Temple, Richard T. Layer, R. Tyler McCabe, Robert M. Jones
-
Patent number: 6727226Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: GrantFiled: July 23, 2001Date of Patent: April 27, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Lourdes J. Cruz, Robert M. Jones, G. Edward Cartier, John D. Wagstaff
-
Publication number: 20040072758Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: ApplicationFiled: October 29, 2003Publication date: April 15, 2004Applicant: Cognetix, Inc.Inventors: John D. Wagstaff, Richard T. Layer, R. Tyler McCabe
-
Patent number: 6696408Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: February 24, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Publication number: 20030224343Abstract: The invention relates to &kgr;-PVIIA-related conotoxins and their use as organ protecting agents, i.e., organ protectants. These conotoxins can be used for arresting, protecting or preserving an organ, such as a circulatory organ, a respiratory organ, a urinary organ, a digestive organ, a reproductive organ, an endocrine organ or a neurological organ. These conotoxins can also be used for arresting, protecting or preserving somatic cells.Type: ApplicationFiled: January 28, 2003Publication date: December 4, 2003Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Karen Pemberton-Goodman, Robert M. Jones, Davis L. Temple, J. Michael McIntosh, Baldomero M. Olivera
-
Patent number: 6630573Abstract: The invention relates to relatively short peptides (termed &tgr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: February 4, 2000Date of Patent: October 7, 2003Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: Craig Walker, Reshma Shetty, Baldomero M. Olivera, David Hooper, Richard Jacobsen, Doug Steele, Robert Jones
-
Patent number: 6624288Abstract: This invention relates to relatively short peptides about 25-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogs to the naturally available peptides, and which include three cyclizing disulfide linkages and one or more &ggr;-carboxyglutamate residues.Type: GrantFiled: December 15, 1998Date of Patent: September 23, 2003Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: Michael Fainzilber, Karel S. Kits, Alma L. Burlingame, Baldomero M. Olivera, Craig Walker, Maren Watkins, Reshma Shetty, Lourdes J. Cruz, Julita Imperial, Clark Colledge
-
Publication number: 20030096361Abstract: The present invention is relates to a &ggr;-carboxylase from Conus snails, a nucleic acid sequence encoding the Conus &ggr;-carboxylase and to a method for using the nucleic acid or protein sequences for preparing &ggr;-carboxylated proteins.Type: ApplicationFiled: August 7, 2002Publication date: May 22, 2003Applicant: Cognetix, Inc.Inventors: James E. Garrett, Pradip K. Bandypadhyay
-
Patent number: 6525021Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for cytoprotection (including neuroprotection and cardioprotection), anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 30, 2000Date of Patent: February 25, 2003Assignee: Cognetix, Inc.Inventors: John D. Wagstaff, R. Tyler McCabe
-
Patent number: 6515103Abstract: The present invention is directed to conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues. The conantokins are useful for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: GrantFiled: May 11, 2000Date of Patent: February 4, 2003Assignees: University of Utah Research Foundation, Cognetix, Inc., Salk InstituteInventors: Fe C. Abogadie, Lourdes J. Cruz, Baldomero M. Olivera, Craig Walker, Clark Colledge, David R. Hillyard, Elsie Jimenez, Richard T. Layer, Li-Ming Zhou, Gregory S. Shen, R. Tyler McCabe, Jean E. Rivier
-
Publication number: 20020198145Abstract: The present invention is directed to the new &mgr;O-conopeptides, their coding sequences and their propeptides and to the use of &mgr;O-conopeptides as a local anesthetic for treating pain. The &mgr;O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.Type: ApplicationFiled: July 20, 2001Publication date: December 26, 2002Applicant: COGNETIX, INC.Inventors: Baldomero M. Olivera, J. Michael McIntosh, R. Tyler McCabe, James E. Garrett, Richard T. Layer, John D. Wagstaff, Robert M. Jones
-
Patent number: 6489298Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: December 3, 2002Assignee: Cognetix, Inc.Inventors: A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Patent number: 6399574Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: GrantFiled: March 22, 2000Date of Patent: June 4, 2002Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: R. Tyler McCabe, Li-Ming Zhou, Richard T. Layer, Baldomero M. Olivera, J. Michael McIntosh
-
Patent number: 6277825Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as pain, e.g., as an analgesic agent.Type: GrantFiled: July 20, 1999Date of Patent: August 21, 2001Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, R. Tyler McCabe, Richard T. Layer, Li-Ming Zhou
-
Patent number: 6268473Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The &agr;-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.Type: GrantFiled: January 21, 2000Date of Patent: July 31, 2001Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, Richard T. Layer, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Robert Schoenfeld, Robert M. Jones
-
Patent number: 6172041Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: GrantFiled: February 10, 1999Date of Patent: January 9, 2001Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: R. Tyler McCabe, Li-Ming Zhou, Richard T. Layer, Baldomero M. Olivera, J. Michael McIntosh